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http:WHAT THIS STUDY ADDS
Stroke causes signiﬁcant deterioration in quality of life (QOL) and functional status. Carotid revascularisation by
endarterectomy or stenting prevents stroke. The ability to maintain preoperative QOL through revascularisation
procedures is an important measure of surgical outcome. This is the ﬁrst systematic review and meta-analysis of
QOL after carotid revascularisation. We provide a useful synthesised modern reference of QOL data that
complements currently available data on the success of carotid revascularisation.Objectives: Stroke causes signiﬁcant quality of life (QOL) deterioration and functional impairment. Carotid
revascularisation by either endarterectomy (CEA) or stenting (CAS) is performed to prevent stroke. The direct
effect of revascularisation on QOL is unclear. This study reviews (a) QOL after CEA, (b) QOL after CAS, (c) QOL
differences between CEA and CAS, and (d) QOL compared with reference populations.
Methods: Medline and Embase were used for sources of data. The PRISMA guidelines were followed. Clinical
studies published after January 1990 were selected using strict eligibility criteria. Quality appraisal and data
tabulation were performed using predetermined forms. Data were synthesised by narrative review and random-
effects meta-analysis using standardised response means. Heterogeneity and bias were assessed.
Results: Twelve studies (4,224 patients), including two randomised controlled trials, were reviewed. Despite an
initial decline in QOL after CEA, quantitative and qualitative analysis of the SF-36 questionnaire showed all
domains returned to baseline by 1 year. Preliminary data suggests that QOL after CAS does not have an initial
decline, especially in physical health domains. QOL is similar between CEA and CAS at 1 year. Comparisons to
reference populations are inconclusive. Meta-analysis was limited by signiﬁcant statistical and methodological
heterogeneity.
Conclusions: Revascularisation by CEA or CAS maintains preoperative QOL. There are minimal differences
between CEA and CAS. This review reafﬁrms the success of carotid revascularisation in preventing the devastating
consequences of stroke on QOL and functional status. Guidelines for future studies are provided.
 2015 European Society for Vascular Surgery. Published by Elsevier Ltd. All rights reserved.
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Stroke is a serious public health problem which commonly
causes persistent disability and poor quality of life (QOL),1e3
QOL being deﬁned as a patient’s perception of health as
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//dx.doi.org/10.1016/j.ejvs.2015.03.020performed to prevent stroke. In ischaemic stroke, 18e29%
are attributable to carotid artery disease6,7 and are pre-
ventable by revascularisation.8
Several key trials have provided strong evidence for CEA
in stroke prevention. NASCET showed CEA is most effective
for symptomatic patients with greater than 70% stenosis.9
Similar results were reported in the ECST trial.10 Findings
from ASCT11 and ASCT-112 suggest the outcomes of CEA in
asymptomatic patients depend on factors including
comorbidities, institutional perioperative stroke and mor-
tality rates, and life expectancy.
Quality of Life After Carotid Revascularisation 635Even though CEA is still the preferred method in most
patients,13 the emergence of CAS has triggered key trials
comparing CAS with CEA. CAS may be more appropriate for
younger patients with favourable anatomy and symptom-
atic patients at high risk of complications from CEA.14 The
SAPPHIRE15 and CREST16 trials, and Carotid Stenting Tria-
lists’ Collaboration meta-analysis17 showed CAS prevents
strokes and is not inferior to CEA. The CREST investigators16
demonstrated a higher periprocedural risk of stroke in CAS
and myocardial infarct in CEA. This has been an important
cause of concern in CAS.
Current data show the combined periprocedural mortal-
ity and stroke rate after CEA is 3.2e6.7% in symptomatic
patients9,13,16,17 and 1.4e3.1% in asymptomatic pa-
tients.11,12,16 After CAS for both asymptomatic and symp-
tomatic patients, periprocedural mortality and stroke are
reported at 4.1e7.7%.13,15e17
Postoperative QOL assessment is recognised by the
World Health Organization and numerous authors as an
important measure of surgical outcome.18e20 QOL data
provide a patient-focused assessment that complements
traditional outcome measures. Current data on the direct
effect of carotid revascularisation on QOL is unclear. This
review aims to ascertain if QOL after carotid revascularisa-
tion is maintained and reﬂects the beneﬁts of stroke pre-
vention and associated post-stroke QOL decline. Hence, the
current investigators conducted a systematic review and
meta-analysis to evaluate (a) QOL after CEA, (b) QOL after
CAS, (c) QOL differences between CEA and CAS, and (d) QOL
compared with reference populations.
MATERIALS AND METHODS
This review was written in accordance with previously
deﬁned guidelines including the PRISMA checklist.21,22Deﬁnition and measurement of quality of life
QOL can be assessed by study-designed questionnaires, and
disease-speciﬁc or generic instruments. These instruments
assess an individual’s physical, emotional and, psychological
health as well as social and functional status.4,5
Individual study-designed questionnaires are constructed
by study authors as arbitrary measures of QOL out-
comes.23e26 Disease-speciﬁc QOL instruments are validated
QOL scoring systems that measure the effect of an illness or
treatment on a speciﬁc condition.5 Generic QOL in-
struments are validated QOL scoring systems that measure
QOL in a broad range of health domains and allow com-
parisons with other conditions and reference populations.5
Generic scoring systems used by studies in this review are
Medical Outcomes Short Form 36 (SF-36),27 Sickness Impact
Proﬁle (SIP),28 Hospital Anxiety and Depression Scale
(HAD),29 Katz Index of Independence in Activities of Daily
Living (ADL),30 European Quality of Life EQ-5D Question-
naire (EQ-5D),31 and the Multidimensional Index of Life
Quality Questionnaire (MILQ).32
Descriptions of each instrument are detailed in the
electronic supplementary table.Selection criteria
Studies considered for review had the following pre-
determined inclusion criteria: (a) all patients over 18 years of
age, (b) asymptomatic or symptomatic carotid stenosis, (c)
ipsilateral CEA or CAS as the procedure, and (d) data recor-
ded on postoperative QOL data compared to preoperative
QOL, reference populations, or other interventions. These
studies were restricted according to the following report
characteristics: (a) published after January 1990, (b) English
language, and (c) original research only. The search period
was chosen to reﬂect modern post-procedure outcomes.
Information sources and search strategy
On June 9, 2014, a literature search was conducted inde-
pendently by two reviewers using MeSH keyword search on
PubMed (MEDLINE) (Fig. 1). Strict inclusion criteria for study
characteristics were applied as described above. An addi-
tional hand search of OVID (MEDLINE) and EBSCOhost
(EMBASE) as well as reference lists of each included study
was conducted to identify studies not found by the initial
MeSH Keyword search.
Study selection
Following the search, two investigators independently per-
formed the ﬁrst stage of screening titles and abstracts.
Studies were excluded if they did not meet eligibility
criteria. If the abstract had insufﬁcient information to
determine eligibility, a second stage screen was run after
data extraction. Consensus for studies to be included was
achieved by discussion between the two investigators based
on the predetermined selection criteria mentioned above.
Investigators were not blinded to any study characteristics.
Data items and extraction
All data items were predetermined and speciﬁed as shown in
Tables 1 and 2. Data extraction was then performed by two
investigators using standardised pilot forms. Study quality
was assessed using sample size, study design, use of validated
QOL measures, follow-up, and level of evidence based on the
Oxford Centre for Evidence Based Medicine33 (Table 1).
Synthesis of results
Qualitative analysis of QOL was performed based on full
data tabulation of results and assessed according to the
aforementioned objectives.
A meta-analysis was performed using the random-effects
model to estimate standardised mean differences for
continuous data across studies. The standardised mean dif-
ferences and pooled-effects (estimated overall effect [95%
conﬁdence interval]) were used as summarymeasures.These
are depicted on Forest plots. An estimated standard devia-
tion could be derived from sample size and 95% conﬁdence
interval values using the formula provided by the Cochrane
handbook for systematic reviews.34 The consistency of re-
sults across studies was assessed by the Tau2 and I2 statistics
for statistical heterogeneity.35,36 A p value <0.05 was
Figure 1. Search algorithm.
636 L. Shan et al.considered signiﬁcant for pooled response means. All sta-
tistical analysis were performed on Review Manager (Rev-
Man) (Windows) version 5.3 (Copenhagen, The Nordic
Cochrane Centre, The Cochrane Collaboration, 2014).
Assessment of bias
The risk of bias in each study was assessed by a qualitative
review based on study quality and data tabulated in Table 1.
RESULTS
After careful systematic selection, 12 studies with 4,224
patients were included for review (Fig. 1).23e26,37e44 The
key reasons for exclusion were lack of QOL data according to
stated eligibility criteria, and studies that were not original
research only. Full details and results of the reviewed arti-
cles are provided in Tables 1 and 2Study characteristics and assessment of bias
Only two studies39,43 used disease-speciﬁc QOL instruments
which are useful measures of change in QOL speciﬁc to a
treatment.5 SF-36 is a recognised QOL instrument in
vascular surgery40 and this was the most commonly used
generic tool.24,26,38e43 Another source of bias pertains to
the QOL instruments used by studies to assess QOL in
longitudinal studies. Though instruments such as QOL and
Euro-QOL are commonly used, these have not been
formally validated for use in longitudinal studies. However,
as there is no consensus as to the best instrument to use,
these are the best available instruments in QOL studies. This
heterogeneity is partially accounted for with random-effects
meta-analysis. Four studies23e26 used self-created ques-
tionnaires that are not previously validated and this is a
potential source of bias.
Table 1. Quality appraisal.
First author year Patients Study
design
Patient demographics Validated QOL
instrument
Disease-speciﬁc Generic Follow-up
method
reported
Response rate Level of
evidence
Sirrka23 1992 84 R Male: NR, Age: 66, Asymptomatic: NR,
Symptomatic: 100%, Level stenosis: “signiﬁcant”
No Study-designed questionnaire No 49% III
Martin24 1998 200 R CEA
Male: 61%, Age: 65, Asymptomatic: 0%,
Symptomatic: 100%, Level stenosis: >70%
Medical treatment
Male: 62%, Age: 66, Asymptomatic: 0%,
Symptomatic: 100%, Level stenosis: <70%
Yes e SF-36 Yes 83% III
Study-designed questionnaire
Vriens44 1998 86 P Male: 78.6%, Age: 64.1 (44e82), Asymptomatic:
17%, Symptomatic: 83%, Level stenosis: NR
Yes e SIP No 81.4% III
Dardik40 2001 50 P Male: 78%, Age: 67.1 (49e83), Asymptomatic:
0%, Symptomatic: 100%, Level stenosis: 89.2%
Yes e SF-36 No NR III
Middleton42 2001 238 R RPAH Hospital
Male: 72.8%, Age: 82.4% < 75, Asymptomatic:
0%, Symptomatic:100%, Level stenosis: NR
CRGH Hospital
Male: 66.4%, Age: 69.9% <75, Asymptomatic:
0%, Symptomatic: 100%, Level stenosis: NR
Yes e SF-36 Yes 90% III
Lloyd41 2004 100 P Male: 64%, Age: 69 (45e87), Asymptomatic:
13%, Symptomatic: 87%, Level stenosis: NR
Yes e SF-36
HAD
EuroQOL (EQ-5D)
Yes 92% III
CaRESS37 2005 397 P CEA
Male: 63%, Age: 71.4, Asymptomatic: 67%,
Symptomatic: 33%, Level stenosis: 89% patients
>75%
CAS
Male: 60%, Age: 71.2, Asymptomatic: 69%,
Symptomatic: 31%, Level stenosis: 82%
Yes e MILQ No NR III
Ogasawara25 2005 92 P Male: 88%, Age: 67.7 (50e75), Asymptomatic:
46%, Symptomatic: 54%, Level of stenosis: 83.4%
No Study-designed questionnaire No 100% III
Abelha38 2008 63 P Male: 76%, Age: 70 (44e84), Asymptomatic:
21%, Symptomatic: 79%, Level stenosis: all
patients 65%
Yes e SF-36
ADL
Yes 76% III
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Table 1-continued
First author year Patients Study
design
Patient demographics Validated QOL
instrument
Disease-speciﬁc Generic Follow-up
method
reported
Response rate Level of
evidence
Stolker43 2010
(SAPHHIRE)
310 RCT CEA
Male: 68%, Age: 72, Asymptomatic: 72%,
Symptomatic: 28%, Level of stenosis:
symptomatic >50%, asymptomatic >80%
CAS
Male: 68%, Age: 72, Asymptomatic: 70%,
Symptomatic: 30%, Level stenosis: symptomatic
>50%, asymptomatic >80%
Yes e SF-36
EuroQol
No >80% (at 1 year:
74% CAS, 67% CEA)
II
Cohen39 2011 (CREST) 2502 RCT Male: 65%, Age: 69, Asymptomatic: 47%,
Symptomatic: 53%, Level stenosis: >85% of
patients >70% stenosis
Yes e SF-36 Yes 85e90% II
Kazmierski26 2012 102 P Male: 70.6%, Age: 65.8 (34e84), Asymptomatic:
0%, Symptomatic: 100%, Level stenosis: >50%
Yes Study-designed questionnaire No 100% III
Abbreviations: ADL ¼ activities of daily living; CaRESS ¼ Carotid Revascularization Using Endarterectomy or Stenting Systems trial; CAS ¼ carotid artery stenting; CEA ¼ carotid
endarterectomy; CREST ¼ Carotid Revascularization Endarterectomy Versus Stenting Trial; HAD ¼ hospital anxiety and depression scale; QOL ¼ quality of life; MILQ ¼ Multidimensional
Index of Life Quality; NA ¼ not applicable; NR ¼ not recorded; P ¼ prospective; R ¼ retrospective; RCT ¼ randomized control trial; SAPPHIRE ¼ Stenting and Angioplasty with
Protection in Patients at High Risk for Endarterectomy; SF-36 ¼ Medical Outcomes Survey Short Form 36 questions; SIP ¼ Sickness Impact Proﬁle.
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Table 2. Quality of life results in included studies.
First author year Procedure Follow-up time Perioperative mortality Perioperative stroke Key ﬁndings
Sirrka23 1992 CEA 8e11 years NR NR Overall QOL similar between CEA and non-
operated groups
Martin24 1998 CEA 1 year 3% 1% SF-36 similar between CEA and medical therapy
Superior improvement in self-perceived general
health and treatment success after CEA
compared to medical therapy
Similar levels of anxiety over future strokes or
TIAs
SF-36 (medical vs. CEA): PF (52.9 vs. 50.5), RP (38.2 vs. 32.4), BP (64.8 vs. 67.5), GHP (53.5 vs. 48.9), VT (49.9 vs. 49.4), SF (66.2 vs. 67.2), RE (51.0 vs. 55.4), MH
(64.4 vs. 68.5)
Perceived change in health (medical vs. CEA): Better reported general health (39% vs. 64%). Reported treatment as “very successful” or “successful” (57% vs.
92%)
Vriens44 1998 CEA 3 months 0% 3% No signiﬁcant change in HRQOL observed 3
months postop.
Signiﬁcant HRQOL improvement after CEA limited
to only patients with contralateral carotid
occlusion.
SIP (preop vs. postop): Overall (74 vs. 72)
Dardik40 2001 CEA 3 months 0% 8% Perceived improved QOL and overall health, but
not change on SF-36 sub-scores.
SF-36 sub-scores for baseline population, preop
and postop groups all similar.
Signiﬁcant improvement in SF-36 score overall
‘change in health score’.
SF-36 (preop vs. postop 3 months): PF (64.6 vs. 59.1, p ¼ .12), RP (40.0 vs. 47.5, p ¼ .22), BP (74.7 vs. 72.9, p ¼ .75), GHP (61.1 vs. 59.8, p ¼ 0.98), VT (57.8 vs.
56.3, p ¼ .70), SF (70.6 vs. 74.9, p ¼ .26), RE (59.3 vs. 64.6, p ¼ .53), MH (75.2 vs. 75.5, p ¼ .52)
No signiﬁcant differences between SF-36 of baseline population, preop and postop sub scores.
Change in health score (preop vs. postop 3 months): 44.5 vs. 61.0, p ¼ .003
Middleton42 2001 CEA 4 years 1.7% NR CEA patients had higher sub-scores in 8 domains.
Majority of patients consider QOL as similar to
preop
15.4% stated health was either “somewhat worse” or “much worse” than a year ago
Mean MOSF SF-36 scores for the 8 domains were higher in CEA cohort than population norms for Australian >55 years old who had experienced a stroke
Lloyd41 2004 CEA 6 months 0% NR Patient self-reported HRQOL did not deteriorate
6 months after surgery
Signiﬁcantly less anxiety after the operation
Signiﬁcant improvement in QOL according to EQ-
5D scale
SF-36 scale (preop vs. postop 6 months): PF (50.7 vs. 51.2), RP (36.9 vs. 41.8), BP (66.3 vs. 64.5), GHP (60.5 vs. 60.1), VT (49.8 vs. 49.7), SF (75.6 vs. 73.9), RE
(61.9 vs. 64.3), MH (71.4 vs. 73.7)
HAD scale: Anxiety (71 vs. 5.9, p < .05), depression (4.4 vs. 4.1)
EQ-5D: TTO (0.61 vs. 0.65), VAS (64.4 vs. 70.2, p < .01)
CaRESS37 2005 CAS CEA 30 days, 1 year 0.0% CAS vs. 0.4% CEA 2.1% CAS vs. 3.6% CEA No signiﬁcant differences between CEA and CAS
groups in change of QOL
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Table 2-continued
First author year Procedure Follow-up time Perioperative mortality Perioperative stroke Key ﬁndings
MILQ (CAS vs. CEA): No signiﬁcant difference at baseline (64 vs. 66)
CAS experienced greater decline in QOL after intervention (4.22 vs. 1.56) but it was not statistically signiﬁcant (p ¼ .319)
Ogasawara25 2005 CEA 1 month 0% 0% Postoperative cerebral hyper-perfusion is
associated with worse QOL due to impaired
cognitive function following CEA
Neuropsychological test scores (preop vs. 1 month postop): WAIS-R VIQ (87.8 vs. 89.4, p ¼ .008), WAIS-R PIQ (88.8 vs. 91.2, p ¼ .002), WMS (96.0, 98.7,
p ¼ .022), ROCF copy (32.3 vs. 32.8, p ¼ NS), ROCF recall (21.6 vs. 23.0, p ¼ .006)
Abelha38 2008 CEA 6 months 0% 4.8% Improved subjective perception of HRQOL.
Higher levels of dependency e higher ADL (Katz,
Lawton).
Decreased HRQOL e lower SF-36 sub-scores
(compared to general population).
SF-36 (General population vs. postop): PF (75.4 vs. 52.0, p < .001), RP (76.7 vs. 50.3, p < .001), BP (65.7 vs. 60.9, p ¼ .11), GHP (59.5 vs. 46.8, p < .001), VT
(57.2 vs. 35.0, p < .001), SF (76.0 vs. 57.6, p < .001), RE (76.9 vs. 53.1, p < .001), MH (66.1 vs. 50.9, p < .001)
SF-36 (ICU surgical population vs. postop): PF (54.1 vs. 52.0, p ¼ .329), RP (45.2 vs. 50.3, p ¼ .183), BP (57.7 vs. 60.9, p ¼ .258), GHP (44.5 vs. 46.8, p ¼ .301),
VT (34.7 vs. 35.0, p ¼ .457), SF (60.2 vs. 57.6, p ¼ .291), RE (50.1 vs. 53.1, p ¼ .299), MH (48.6 vs. 50.9, .261)
63% reported better general health compared to 12 months prior and 11% reported worse general health
ADL (Preop vs. postop): Katz scale (0.26 vs. 0.56, p ¼ .047), dependency in personal ADL (12% vs. 33%, p ¼ .186), Lawton scale (5.91 vs. 4.28, p < .001),
dependency in instrumental ADL (26% vs. 65%, p ¼ .164)
Stolker43 2010 (SAPPHIRE) CAS, CEA 2 weeks, 1 month, 6 months, 12 months CAS 7.0% vs. CEA 12.9% CAS 5.8% vs. CEA 7.7% Better SF-36 scores for CAS at 2 weeks compared
to CEA, but not after 1 month
SF-36 (CAS vs. CEA): 2 weeks: CAS patients had better scores in SF-36 physical scale (mean difference 8.8 role physical). 1 month: no signiﬁcant difference
6 months: no signiﬁcant difference. 12 months: no signiﬁcant difference
SF-36 mean difference at 12 months (CAS vs. CEA): PF (7.7), RP (4.8), BP (7.0), GHP (10.1), VT (5.9)
EQ-5D utility score (CAS vs. CEA): 0.01klll
Symptoms/side effects: At 2 weeks CAS patients reported less difﬁculty eating, swallowing, difﬁculty driving and less neck pain. These differences resolved by
the 1-month follow-up assessment
Cohen39 2011 (CREST) CAS
CEA
2 weeks, 1 month, 1 year CAS 7.2% vs. CEA 6.8% 4.1% CAS vs. 2.3% CEA Better SF-36 scores for CAS at 2 weeks compared
to CEA (SF-36, disease speciﬁc scales, pain scale),
but not after 1 month. Same at 1 year
SF-36: 2 weeks: CAS group had better scores than CEA group for 5/8 measures (role physical greatest difference). 1 month: CAS group had better scores for 3/
8. 1 year: no signiﬁcant difference
SF-36 mean difference at 12 months (CAS vs. CEA): PF (0.8), RP (2.0), BP (0.2), GHP (0.1), VT (0), SF (1.2), RE (1.1), MH (0.4)
Pain out of 10 (CAS vs. CEA): Baseline (3.1 vs. 3.0, p ¼ .23), 2 weeks (2.9 vs. 3.1, p < .01), 1 month (3.0 vs. 3.1, p ¼ .16). 12 months: no difference (3.0 vs. 3.0,
p ¼ .86)
Kazmierski26 2012 CEA 1 year NR NR Mean QOL increased 1 year after surgery
Less symptoms
Mean QOL after surgery increased (3.0 vs. 6.3, p < .001) 1 year after surgery
Before surgery: “poor” (more than half). After surgery “good” (86%)
Vertigo, headache, recurrent syncope, aphasia, cerebral stroke less common after CEA
Abbreviations: ADL ¼ activities of daily living; BP ¼ bodily pain; CaRESS ¼ Carotid Revascularization Using Endarterectomy or Stenting Systems trial; CAS ¼ carotid artery stenting;
CEA ¼ carotid endarterectomy; CREST ¼ Carotid Revascularization Endarterectomy Versus Stenting Trial; EQ-5D ¼ European quality of life questionnaire EQ-5D; GHP ¼ general health
perception; QOL ¼ quality of life; ICU ¼ intensive care unit; MH ¼ mental health; MILQ ¼ Multidimensional Index of Life Quality; NA ¼ not applicable; NR ¼ not recorded; NS ¼ not
signiﬁcant; PF ¼ physical function; postop ¼ postoperative; preop ¼ preoperative; RE ¼ role emotional/mental; RP ¼ role physical; SAPPHIRE ¼ Stenting and Angioplasty with
Protection in Patients at High Risk for Endarterectomy; SF ¼ social functioning; SF-36 ¼Medical Outcomes Survey Short Form 36 questions; VAS ¼ visual analogue scale; VT ¼ energy/vitality.
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Quality of Life After Carotid Revascularisation 641The majority of studies were prospective,25,26,37e41,43,44
including two randomised controlled trials.39,43 QOL assess-
ment should be performed prospectively due to the sub-
jective nature of QOL. The three retrospective studies23,24,42
are included as an impartial part of the comprehensive re-
view to provide a perspective on current data. However,
these are associated with bias. Overall there were two
studies of level 2 evidence39,43 and 10 studies of level 3 ev-
idence23e26,37,38,40e42,44 based on the Oxford criteria.
Themedian follow-up was 12months (range 2 weeks to 11
years). There was a lack of studies with longer follow-up or
comparisons with reference populations. According to pre-
vious guidelines, a response rate of >85% (loss to follow-
up < 15%) is considered ideal.45 This was achieved in ﬁve
studies.25,26,39,41,42 Any patients who did not participate in
QOL assessment or were lost to follow-up weremore likely to
have a worse QOL due to a greater burden of comorbidities
and physical impairments.38,43 Pertinent examples are post-
operative stroke and death. This includes comparisons be-
tween CEA and CAS. However, this is a limitation in all surgical
literature on QOL. Indeed, all surgical outcomes are limited
by mortality and the presence severe postoperative com-
plications should not preclude QOL assessment. Despite this,
studies in this review with a high response rate demon-
strated similar results to studies with lower response rates.
Signiﬁcant heterogeneity was present among studies due
to differences in patient demographics, level of stenosis,
symptomatic status, surgical risk, follow-up times, and QOL
instruments. In particular, CEA and CAS were performed on
both symptomatic and asymptomatic patients without
distinction. Thus, whether the observed differences in QOL
outcomes should be attributed to treatment or recovery
from previous stroke remains to be elicited. Amongst
studies included for meta-analysis, statistical heterogeneity
was acceptable (Tau2 range 0e0.02, I2 range 0e67%).Mortality and morbidity
Eight studies evaluated postoperative morbidity and
mortality26,37e40,42e44. After CEA, perioperative mortality
and stroke rates in included studies were 0.0e2.0% and
2.3e8.0%, respectively.15,16,26,37e40,42e44 Perioperative
mortality and stroke rates after CAS were 0.0e0.7% and
2.1e4.1%, respectively.15,16,37,39,43 Combined perioperative
stroke or death or post-procedural stroke rates were 2.3e
3.6% for CEA and 2.1e4.4% for CAS.16,37,39 Perioperative
myocardial infarction was 0.8e6.6% in CEA and 0.0e1.9% in
CAS.15,16,37,39,43 The 1-year stroke rates for CEA and CAS
were 7.7e9.8% and 5.5e5.8%, respectively.15,37,43 These
are comparable with previous trials.9,11,13,15e17,46
Few studies reported comprehensive morbidity data.
Patients in included studies experienced fewer neurological
symptoms after CEA, including vertigo, headache, syncope,
aphasia and amaurosis fugax.26 Symptoms including head-
ache and leg pain were similar in CEA and CAS after 1
year,39 although there may be more neck pain with CEA.43
Cranial nerve palsies occurred in 0.3% and 4.7% of CAS
and CEA patients respectively.39Quality of life results
Quality of life after carotid endarterectomy (10
studies)23,25,26,38e44. A limited meta-analysis was per-
formed on three studies comparing post-procedure and pre-
procedure QOL following CEA (two studies level 2 evidence;
one study level 3 evidence).39,41,43 Statistically signiﬁcant,
but small magnitude improvements were identiﬁed in SF-36
scores after CEA (Fig. 2).
Both randomised trials demonstrated that at 2 weeks
after CEA, SF-36 physical function, role physical, vitality,
bodily pain, and social function domains were temporarily
worse, but role emotional, mental health and general
health were similar.39,43 Role physical, role emotional, social
function, mental health, vitality, bodily pain, and general
health are similar or better at 3 months, but physical
function appears to be worse.40 This is reﬂected by similar
changes in SIP scores.44 At 6 months, QOL is similar in all SF-
36 domains and EQ-5D scores.41 Patients also appear have
lower levels of anxiety.41 By 1 year, all SF-36 domains were
similar to pre-procedure levels in the randomised trials.39,43
Overall, 63e86% patients reported a better QOL26,38 and
57% reported QOL42 similar as to before surgery. Sirkka
et al.23 were the only authors to report long-term QOL
outcomes and showed good recovery in QOL and cognitive
status after surgery that was maintained until 8 years.
There was an increased level of dependency in functional
status at 6 months after surgery, with 65% of patients
dependent in at least one instrumental ADL and 33% in at
least one personal ADL.38 Two studies report that at 1esix
6, work, leisure, and social relations may be negatively
impacted by cognitive decline due to cerebral hypo-
perfusion or emboli.25,41
Quality of life after carotid stenting (two studies)39,43. The
two randomised trials showed CAS does not negatively
impact SF-36 scores at 2 weeks, but general health and
bodily pain were slightly worse at 1 month.39,43 All domains
improve steadily after 1 month and are comparable with
pre-procedure QOL at 1 year.39,43
Quality of life after endarterectomy compared with
stenting (three studies)37,39,43. Cohen et al.39 reported that
physical function, role physical, vitality, bodily pain, and
social function are superior after CAS than CEA at 2 weeks.
Stolker et al.43 reported only vitality was better in CAS at 2
weeks. These differences are not present at 1 year, with
similar QOL for CEA and CAS in all domains of SF-36 and
MILQ.37,39,43 A similar pattern is observed in functional
performance with no difference in walking, eating, and
driving ability by 1 year.39 Mental health and role emotional
do not appear to be impacted by type of procedure.39,43
Quality of life after carotid revascularisation compared
with reference populations (four studies)24,38,40,42. Mid-
dleton et al.42 showed that after 3 months, all SF-36 domains
are better than the general population who have had a pre-
vious stroke, but remain worse than patients without previ-
ous stroke. In contrast, Dardik et al.40 reported worse SF-36
Figure 2. Meta-analysis of SF-36 scores after carotid endarterectomy.
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Quality of Life After Carotid Revascularisation 643scores in all domains at 3months. SF-36 scores after CEAwere
similar in all domains except bodily painwhen comparedwith
the general population at 6 months.38 Martin et al.24 showed
that a greater proportion of patients after stroke report
better health and satisfaction and lesser anxiety after CEA
than CAS, but both CEA and medical management cohorts
had worse SF-36 scores than the general population.
DISCUSSION
Summary of evidence and interpretation
There have been numerous randomised trials on CEA and
CAS in various subgroups of patients,9,11,13,15e17,46 but QOL
outcomes have not been adequately delineated. This review
demonstrates the direct effect of carotid revascularisation
in maintaining preoperative QOL and provides an important
adjunct to traditional outcome measures such as stroke and
death.
Included studies demonstrate that CEA maintains preop-
erative QOL. Individually, studies reported improvements in
some health domains, but collectively all studies showed
that by 6 months to 1 year, all domains are at least as good as
preoperatively. QOL should not be expected to be superior to
baseline, particularly for previously asymptomatic patients
who have prophylactic procedures. Studies demonstrated a
temporary decline in the early postoperative period, partic-
ularly in physical health. This is only transient and is consis-
tent with the expected initial recovery period required after
open surgery. Mental health domains did not demonstrate
this initial decline; this may be due to a high baseline level of
anxiety and poor perception of health in patients with ca-
rotid stenosis who are also likely to have poor overall car-
diovascular health.41 Results of meta-analysis were additive
and supported these qualitative ﬁndings.
CAS procedures increased from 3% to 13% of all carotid
revascularisation procedures in just 10 years to 2008,1
necessitating QOL data after CAS as well as comparisons
with CEA. Studies in this review indicate no decline in QOL
after CAS, although some health domains were temporarily
worse in the CAS group. QOL at 1 year is similar to baseline.
These preliminary studies suggest CAS is superior to CEA in
the early post-procedure period in physical health domains
from as early as 2 weeks. However, these differences were
not present at 1 year. Based on these results where QOL is
similar, the choice between CEA and CAS may be inﬂuenced
by a variety of other factors including surgical risk and pa-
tient preference.
Current evidence suggests either CEA or CAS are indicated
in most symptomatic patients with greater than 70% ipsi-
lateral stenosis, selected patients with 50e69% ipsilateral
stenosis, and a selected subgroup of patients with asymp-
tomatic stenosis.14 CEA remains the current gold standard
and is still the treatment of choice for most patients. From a
technical perspective, trials show CAS is comparable with
CEA, but periprocedural stroke may be more frequent with
CAS and myocardial infarction may be more frequent with
CEA.16,17,47 Further investigation will be required to more
clearly delineate the ﬁndings of these early studies.There were mixed QOL results in comparison with
reference populations. QOL may be superior to the stroke
population, but data are inconclusive and interpretation is
limited by heterogeneous comparison groups and a lack of
matching for patient demographics.
A key limitation of this review is that only a limited meta-
analysis could be performed. Key factors were lack of sta-
tistical data (no mean and standard deviation values, no
preoperative and postoperative data) and methodological
heterogeneity (different QOL scoring systems that could not
be pooled together, different comparison groups). Despite
this, meta-analysis provided additional support for the pri-
mary qualitative analysis. Statistically relevant heterogene-
ity as reﬂected by the Tau2 and I2 statistic was acceptable,34
although the inclusion of levels 2 and 3 evidence may have
weakened the ﬁndings. Owing to the limited number of
studies on this topic, studies were not excluded if they were
not randomised controlled trials. It would also be ethically
challenging to randomise patients and deny revascularisa-
tion purely to assess QOL outcomes. Thus assessment of
QOL in various control groups is also difﬁcult to interpret.
This is the ﬁrst systematic review on QOL after carotid
revascularisation and provides a synthesised modern
reference that complements currently available data on the
success of carotid revascularisation. Patients can also have a
more realistic expectation of postoperative QOL.Implications for future research
There are several issues identiﬁed from this study that
should be addressed in future studies.
Consistent disease-speciﬁc and generic QOL instruments
should be used to facilitate comparison between studies.
Only validated instruments should be used, including a
formal validation for use in longitudinal studies. The SF-36
instrument would be preferred.
Several statistical parameters should be kept consistent
to allow for more complete meta-analysis. QOL data should
be expressed as mean  standard deviation and results
given at predetermined follow-up time points, including
baseline and ﬁnal follow-up.
Emphasis should also be placed on QOL after CAS and
effect of both CEA and CAS in asymptomatic patients. This
includes comparisons between CEA and other methods of
revascularisation.
The effect of morbidity as a variable for QOL outcomes is
underappreciated. This would be particularly relevant in
determining what would be an acceptable decline in QOL in
order for revascularisation to be worthwhile.
Finally, it is clear from this review that many more studies
are required to allow meta-analyses of QOL outcomes of a
speciﬁc intervention and comparison group. In particular,
prospective rather than retrospective studies are required
to minimise bias.
CONCLUSION
This review reafﬁrms the success of carotid revascularisa-
tion in preventing the devastating consequences of stroke
644 L. Shan et al.on QOL. CEA and CAS maintain preoperative QOL for at
least 1 year. Preliminary data suggest CAS may be advan-
tageous over CEA in physical health domains. This difference
is not present at 1 year. Data on comparisons with reference
populations are inconclusive. This review should be a
catalyst for further studies based on the outlined guidelines.
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